IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.

Taltz (ixekizumab) - Eli Lilly

Bimzelx (bimekizumab-bkzx) - UCB

Cosentyx (secukinumab) - Novartis

izokibep (ABY-035) - Affibody

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

http://www.ncbi.nlm.nih.gov/pubmed/42661716

Abdallah Dwayat; Alhareth M Amro; Amro Odeh; Anas K Assi; Habeeb H Awwad; Laith Alamlih; Mohammad Alfrookh; Mohammad W Awlad Mohammad; Mohammad Yasini; Mohammed Ehmidat; Salahaldeen Deeb; Yahya Kayed AbuJwaid; Yousef Albow

Aug 29, 2026